A
Anju Bhardwaj
Researcher at Harvard University
Publications - 50
Citations - 1582
Anju Bhardwaj is an academic researcher from Harvard University. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 17, co-authored 32 publications receiving 1408 citations. Previous affiliations of Anju Bhardwaj include Case Western Reserve University.
Papers
More filters
Journal ArticleDOI
Use of Amino-Terminal Pro–B-Type Natriuretic Peptide to Guide Outpatient Therapy of Patients With Chronic Left Ventricular Systolic Dysfunction
James L. Januzzi,Shafiq U. Rehman,Asim A. Mohammed,Anju Bhardwaj,Linda Barajas,Justine Barajas,Han Na Kim,Aaron L. Baggish,Rory B. Weiner,Annabel Chen-Tournoux,Jane E. Marshall,Stephanie A. Moore,William D. Carlson,Gregory D. Lewis,Jordan T. Shin,Dorothy Sullivan,Kimberly A. Parks,Thomas J. Wang,Shawn A. Gregory,Shanmugam Uthamalingam,Marc J. Semigran +20 more
TL;DR: In patients with HF due to LV systolic dysfunction, NT-proBNP-guided therapy was superior to SOC, with reduced event rates, improved quality of life, and favorable effects on cardiac remodeling.
Journal ArticleDOI
Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure.
Hanna K. Gaggin,Jackie Szymonifka,Anju Bhardwaj,Arianna M. Belcher,Benedetta De Berardinis,Shweta R. Motiwala,Thomas J. Wang,James L. Januzzi +7 more
TL;DR: Baseline values of all 3 novel biomarkers independently predicted total CV events even after adjusting for clinical and biochemical characteristics, including NT-proBNP, with the best model including all 3 biomarkers showing the most promise.
Journal ArticleDOI
Soluble Concentrations of the Interleukin Receptor Family Member ST2 and β-Blocker Therapy in Chronic Heart Failure
TL;DR: Although BB therapy exerted dose-related benefits across all study participants, sST2 measurement identifies patients with chronic heart failure who may particularly benefit from higher BB doses.
Journal ArticleDOI
Influence of Transcatheter Aortic Valve Replacement Strategy and Valve Design on Stroke After Transcatheter Aortic Valve Replacement : A Meta-Analysis and Systematic Review of Literature
Ganesh Athappan,R. Dilip Gajulapalli,Prasanna Sengodan,Anju Bhardwaj,Stephen G. Ellis,Lars G. Svensson,Emin Murat Tuzcu,Samir R. Kapadia +7 more
TL;DR: In this paper, the risk of stroke after transcatheter aortic valve replacement (TAVR) was compared with transapical and transfemoral valve types and valve designs.
Journal ArticleDOI
Serial measurement of galectin‐3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study
Shweta R. Motiwala,Jackie Szymonifka,Arianna M. Belcher,Rory B. Weiner,Aaron L. Baggish,Patrick M. Sluss,Hanna K. Gaggin,Anju Bhardwaj,James L. Januzzi +8 more
TL;DR: The value of serial galectin‐3 measurement for prognosis and response to therapy in chronic HF is examined and it is found that it may mediate cardiac fibrosis.